Profitability:
Profitability is supported by strong adjusted EBITDA margins, with 2025 at roughly one‑third of revenue and Q1 2026 near that level as tighter cost control held despite mix shifts. This indicates stable profit generation during a transition toward newer businesses.
Product Line Growth:
Product lines tied to Pharma Direct and condition‑specific subscriptions are expanding rapidly, with Pharma Direct accelerating year over year and subscriptions returning to growth in Q1 2026. This momentum reflects successful scaling of newer offerings like GLP‑1 weight‑loss programs.
Diversified Revenue Streams:
The business is leaning into Pharma Direct and rebuilding subscriptions to offset softness in core prescription transactions over time. Management explicitly positioned Pharma Direct as central to future growth, broadening the mix beyond discount‑card transactions.
